OSCR
Oscar Health, Inc.
OSCR has the edge over RPID overall, supported by stronger fundamentals and lower modeled downside.
RPID
Rapid Micro Biosystems, Inc.
RPID offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RPID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
RPID's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
RPID PE Valuation
RPID has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
RPID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect RPID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over RPID on earnings quality, reporting a profit while its opponent remains loss making.
RPID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.10 | -$0.09 |
| Q1 2026 | -$1.10 | -$0.07 |
| Q4 2025 | -$1.05 | +$0.03 |
| Q3 2025 | -$1.01 | +$0.11 |
| Q2 2025 | -$1.01 | +$0.16 |
| Q1 2025 | -$1.03 | +$0.18 |
| Q4 2024 | -$1.08 | +$0.14 |
| Q3 2024 | -$1.12 | +$0.23 |
RPID is still losing money, but less than at its worst: $1.10 per share over the past year, against $1.62 at its worst in early 2021.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RPID on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over RPID on profitability, with a higher operating margin.
RPID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.1M | +11% |
| Q1 2026 | $8M | +11% |
| Q4 2025 | $11.3M | +37% |
| Q3 2025 | $7.8M | +3.1% |
| Q2 2025 | $7.3M | +9.7% |
| Q1 2025 | $7.2M | +28% |
| Q4 2024 | $8.2M | +30% |
| Q3 2024 | $7.6M | +24% |
RPID's revenue has grown year over year for 14 quarters in a row: $8M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -153% | +14 points |
| Q1 2026 | -173% | -11 points |
| Q4 2025 | -108% | +16 points |
| Q3 2025 | -145% | +13 points |
| Q2 2025 | -167% | +35 points |
| Q1 2025 | -162% | +93 points |
| Q4 2024 | -124% | +68 points |
| Q3 2024 | -158% | +77 points |
RPID's operating margin was −153% last quarter, up 14 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over RPID on cash generation, producing positive trailing cash flow while its opponent burns cash.
RPID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$12.5M | -$2.4M |
| Q1 2026 | -$15.5M | -$6.1M |
| Q4 2025 | -$3.3M | +$6.7M |
| Q3 2025 | -$9.1M | -$301K |
| Q2 2025 | -$10.1M | +$512K |
| Q1 2025 | -$9.4M | +$6.7M |
| Q4 2024 | -$10M | -$92K |
| Q3 2024 | -$8.8M | +$1.3M |
RPID has burned cash in almost every quarter: −$40M over the past year, against −$38M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RPID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.4% | +2.9M shares |
| 1 year | +8.3% | +3.7M shares |
| 3 years | +12% | +5.3M shares |
| 5 years | +52% | +16.6M shares |
RPID has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
RPID Net Leverage
RPID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RPID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.6 | Oversold |
| Stochastic | 4.6 | Oversold |
RPID's weekly RSI is 25 (oversold) and its Stochastic is 5 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RPID PE vs Healthcare Sector
RPID has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over RPID on trend strength, trading above more of its moving averages.
RPID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.81 | 17% below |
| 20 week MA | $1.34 | 50% below |
| 50 week MA | $2.29 | 71% below |
| 100 week MA | $2.57 | 74% below |
| 200 week MA | $1.78 | 62% below |
RPID is in a downtrend: it's below all five of its weekly moving averages, and 62% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RPID on returns for 2026, with the stronger performance.
RPID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.1 | $11.3 | -53% |
| 2022 | $11.3 | $1.43 | -87% |
| 2023 | $1.43 | $0.74 | -48% |
| 2024 | $0.74 | $0.96 | +30% |
| 2025 | $0.96 | $2.98 | +210% |
| 2026 YTD | $2.98 | $0.67 | -78% |
RPID's yearly returns have swung widely, from +210% in 2025 to −87% in 2022. It's down 78% so far in 2026.